A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggr...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2019
Main Authors: Flørenes, Vivi Ann, Flem-Karlsen, Karine, McFadden, Erin, Bergheim, Inger Riise, Nygaard, Vigdis, Nygård, Vegard Mokleiv, Farstad, Inger Nina, Øy, Geir Frode, Emilsen, Elisabeth, Fleten, Karianne Giller, Ree, Anne Hansen, Flatmark, Kjersti, Gullestad, Hans Petter, Hermann, Robert, Ryder, Truls, Wernhoff, Patrik, Mælandsmo, Gunhild Mari
Format: Article
Language:Norwegian
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived xenografts (PDXs) to clinical relevant drugs for 7 days, and examined its potential to evaluate therapy response. A strong association between Vemurafenib response and BRAF mutation status was achieved (P 
ISSN:1936-5233
1936-5233